Novo Nordisk is expected to unveil a major corporate rebrand tomorrow, shortening its name to simply Novo, adopting the slogan “Lasting health starts now,” also turning the company’s familiar Apis bull logo so that it faces the opposite direction. Forward. Danish reporting suggests the changes are part of a broader effort to make the company more customer focused and signal a new chapter for one of the most important companies in obesity medicine.
The timing is notable because Novo no longer defines the “GLP-1 market”, it is fighting to simply keep pace with a market increasingly dominated by Lilly’s tirzepatide. For patients, the real interest will not be the new name or logo, but what this reset means for the medicines they already use and the treatments still to come.
Patients Want More Than a Rebrand
Novo deserves all the credit for ushering in the modern GLP-1 era with liraglutide and semaglutide, but access remains one of the biggest frustrations in obesity care. Patients are still navigating insurance exclusions, prior authorizations, high cash prices, and inconsistent coverage, so a company promising to become more customer focused will inevitably face questions about whether that means better pricing and easier access.
There is also growing pressure on Novo to show where obesity medicine goes next. Lilly has already raised expectations with tirzepatide, and retatrutide could push the efficacy bar higher still. CagriSema has been submitted, but its trial results did not outperform tirzepatide on weight loss or diabetes outcomes, even though Novo designed REDEFINE to better reflect real-world use rather than simply push patients to maximum tolerated doses for the biggest headline number.
That may leave the next-generation efficacy story feeling underwhelming in a world where hundreds of thousands of patients have already “gone gray” to try retatrutide before approval. But Novo has a different opportunity to define its next era, if they choose to truly seize the moment. If “lasting health starts now” is going to truly mean something, Novo could lead where patients may feel it most, on price and access.
Patient Takeaways
The most important part of tomorrow’s announcement will not be whether Novo drops “Nordisk” from its name, or which direction the Apis bull faces. Patients will be watching for actual signs that the company intends to make its current treatments easier to access while also accelerating the next generation of obesity medicines.
Competition between Novo, Lilly, and the growing number of companies entering obesity medicine could usher in the Golden Age of obesity medicine. Better drugs, more treatment options, and ultimately more downward pressure on pricing. Novo could lead the way with dramatic price drops today. This is what would truly turn “Lasting health starts now” from a branding exercise into something patients can actually feel. We will be watching.
Leave a heart below if you want to see a price drop more than a rebrand
